<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01318967</url>
  </required_header>
  <id_info>
    <org_study_id>0537GCRC</org_study_id>
    <nct_id>NCT01318967</nct_id>
  </id_info>
  <brief_title>Measurement of Kidney Blood Flow and Oxygen Levels by MRI</brief_title>
  <official_title>MRI for the Non-invasive Determination of Renal Blood Flow and Renal Oxygenation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of renal blood flow measurements by PAH clearance and MRI
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The traditional measurement of renal blood flow in ml/min involves the collection of multiple
      blood and urine samples after an infusion of a drug called para-aminohippurate (PAH) is
      given. In this study, the investigators determine the ability of MRI to estimate renal blood
      flow. The primary hypothesis is that renal blood flow as measured by PAH clearance is similar
      to renal blood flow as estimated by MRI. The measurements by PAH clearance and MRI are both
      performed on the same day.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of Renal Blood Flow of the Kidney by the PAH Method</measure>
    <time_frame>Renal blood flow is estimated over 1 hour by PAH</time_frame>
    <description>Renal blood flow is estimated by the PAH method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of Regional Blood Oxygenation by MRI</measure>
    <time_frame>One measure after furosemide (day 1)</time_frame>
    <description>Estimate of renal blood flow by using MRI scans before and after the administration of furosemide</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>PAH</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PAH measure of renal blood flow is first performed on subjects prior to administration of furosemide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRI after furosemide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After the PAH measurement is complete, subjects receive 20 mg furosemide and undergo BOLD MRI to estimate renal blood flow</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>Renal blood flow is measured after the administration of 20 mg of furosemide during MRI scan only.</description>
    <arm_group_label>MRI after furosemide</arm_group_label>
    <other_name>Lasix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>PAH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        In this study, the investigators will enroll 16 men and women aged â‰¥ 18 years with Stage II
        - V chronic kidney disease (CKD). In addition, the investigators will enroll 4 subjects
        with a glomerular filtration rate (GFR) of greater than 60 ml/min who do not have any
        evidence of CKD.

        Exclusion Criteria:

        This study excludes those not suitable for MRI or for the interventional pharmacologic
        procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Rocco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2011</study_first_submitted>
  <study_first_submitted_qc>March 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2011</study_first_posted>
  <results_first_submitted>December 8, 2014</results_first_submitted>
  <results_first_submitted_qc>April 8, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 10, 2015</results_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal blood flow</keyword>
  <keyword>Regional renal blood flow</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Furosemide</title>
          <description>With and without furosemide
Furosemide: Renal blood flow is measured before and after the administration of 20 mg of furosemide.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Furosemide</title>
          <description>With and without furosemide
Furosemide: Renal blood flow is measured before and after the administration of 20 mg of furosemide.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measurement of Renal Blood Flow of the Kidney by the PAH Method</title>
        <description>Renal blood flow is estimated by the PAH method.</description>
        <time_frame>Renal blood flow is estimated over 1 hour by PAH</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Furosemide</title>
            <description>With and without furosemide
Furosemide: Renal blood flow is measured before and after the administration of 20 mg of furosemide.
Renal blood flow is measured by PAH method and by MRI method</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Renal Blood Flow of the Kidney by the PAH Method</title>
          <description>Renal blood flow is estimated by the PAH method.</description>
          <units>ml/min</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190" lower_limit="47" upper_limit="342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of Regional Blood Oxygenation by MRI</title>
        <description>Estimate of renal blood flow by using MRI scans before and after the administration of furosemide</description>
        <time_frame>One measure after furosemide (day 1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MRI After Furosemide</title>
            <description>After the PAH measurement is complete, subjects receive 20 mg furosemide and undergo BOLD MRI to estimate renal blood flow
Furosemide: Renal blood flow is measured after the administration of 20 mg of furosemide during MRI scan only.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Regional Blood Oxygenation by MRI</title>
          <description>Estimate of renal blood flow by using MRI scans before and after the administration of furosemide</description>
          <units>ml/min</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300" lower_limit="69" upper_limit="620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Furosemide</title>
          <description>With and without furosemide
Furosemide: Renal blood flow is measured before and after the administration of 20 mg of furosemide.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Rocco, MD</name_or_title>
      <organization>Wake Forest School of Medicine</organization>
      <phone>336-716-4650</phone>
      <email>mrocco@wfubmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

